UY25374A1 - Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina - Google Patents

Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina

Info

Publication number
UY25374A1
UY25374A1 UY25374A UY25374A UY25374A1 UY 25374 A1 UY25374 A1 UY 25374A1 UY 25374 A UY25374 A UY 25374A UY 25374 A UY25374 A UY 25374A UY 25374 A1 UY25374 A1 UY 25374A1
Authority
UY
Uruguay
Prior art keywords
amount
sexual dysfunction
female sexual
treatment
ampomorphine
Prior art date
Application number
UY25374A
Other languages
English (en)
Inventor
El-Rashidy Bruce Ronsen Ragab
El-Rashidy Ragab
Bruce Ronsen
Original Assignee
Pentech Pharmaceuticals Inc Anillinois Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc Anillinois Corp filed Critical Pentech Pharmaceuticals Inc Anillinois Corp
Publication of UY25374A1 publication Critical patent/UY25374A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Forma de dosificación sublingual para el mejoramiento de la disfunción sexual femenina, que comprende apomorfina o una sal de adición de ácido farmacéuticamente aceptable de la misma, contenida en una cantidad de 2 miligramos a 12 miligramos de ampomorfina, de modo que la cantidad útil sea suficiente para incrementar el flujo de sangre intraclitorial y el flujo sanguíneo de las paredes vaginales que se produce por estimulación de de dicha mujer, pero menos que la cantidad que provoca náuseas; la dosis puede también comprender una beta-ciclodextrina (más particularmente hidroxipropil-beta-ciclodextrina). La forma de dosificación también puede incluir manitol y ácido ascórbico. Se incluye en especial una dosificación que comprende ampomorfina o sal de adición de la misma en una cantidad suficiente para mantener la concentración del plasma entre 1 a 2 nanogramos por milímetro de plasma durante la actividad sexual.
UY25374A 1998-01-30 1999-01-29 Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina UY25374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/016,252 US5945117A (en) 1998-01-30 1998-01-30 Treatment of female sexual dysfunction

Publications (1)

Publication Number Publication Date
UY25374A1 true UY25374A1 (es) 1999-09-27

Family

ID=21776169

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25374A UY25374A1 (es) 1998-01-30 1999-01-29 Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina

Country Status (34)

Country Link
US (2) US5945117A (es)
EP (1) EP1056419A4 (es)
JP (1) JP2002501875A (es)
KR (1) KR20010040477A (es)
CN (1) CN1250221C (es)
AR (1) AR017976A1 (es)
AU (1) AU752928B2 (es)
BG (1) BG64667B1 (es)
BR (1) BR9908038A (es)
CA (1) CA2322289A1 (es)
CO (1) CO4970819A1 (es)
CR (1) CR5959A (es)
DZ (1) DZ2714A1 (es)
GC (1) GC0000096A (es)
GT (1) GT199900013A (es)
HK (1) HK1040901B (es)
HN (1) HN1999000015A (es)
HU (1) HUP0101268A3 (es)
IL (2) IL137569A0 (es)
JO (1) JO2085B1 (es)
MA (1) MA26600A1 (es)
MX (1) MXPA00007447A (es)
NO (1) NO319821B1 (es)
NZ (1) NZ506597A (es)
PA (1) PA8467801A1 (es)
PE (1) PE20000240A1 (es)
PL (1) PL194350B1 (es)
SK (1) SK11362000A3 (es)
TN (1) TNSN99008A1 (es)
TR (1) TR200002220T2 (es)
TW (1) TW550069B (es)
UY (1) UY25374A1 (es)
WO (1) WO1999038467A1 (es)
ZA (1) ZA99686B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
WO1999066909A2 (en) * 1998-06-22 1999-12-29 Univ Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
CZ20023637A3 (cs) 2000-04-07 2003-02-12 Tap Pharmaceutical Products, Inc. Deriváty apomorfinu a způsoby jejich použití
CA2408399A1 (en) * 2000-05-09 2001-11-15 Nitromed, Inc. Infrared thermography and methods of use
AU2001273636A1 (en) 2000-06-27 2002-01-08 Qualilife Pharmaceuticals Inc. Compositions and methods for treating females sexual response
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
US6528521B2 (en) 2000-11-15 2003-03-04 Tap Pharmaceutical Products, Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
ATE358483T1 (de) * 2000-11-22 2007-04-15 Abbott Lab Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
WO2002062315A1 (en) * 2001-02-08 2002-08-15 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
AU2003223304A1 (en) * 2002-03-19 2003-10-08 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
CA2445212A1 (en) * 2002-10-10 2004-04-10 Queen's University At Kingston Treatment of sexual dysfunction
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
WO2005105763A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
EP1863484A1 (en) * 2005-03-21 2007-12-12 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
ATE412648T1 (de) * 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
JP5256425B2 (ja) * 2005-04-08 2013-08-07 リングアル コンセグナ ピーティーワイ エルティーディー 口腔送達システム
US20100222365A1 (en) * 2005-08-10 2010-09-02 Pfizer Inc Substituted triazole deriviatives as oxytocin antagonists
CA2914168C (en) 2006-03-28 2018-05-08 Atir Holding S.A. Pyrido[1,2-a]pyrimidin-4-one derivatives and their use in the treatment of sexual disorders
US7800094B2 (en) * 2007-06-11 2010-09-21 Macronix International Co., Ltd. Resistance memory with tungsten compound and manufacturing
EP2442650B1 (en) 2009-06-12 2015-08-26 Cynapsus Therapeutics Inc. Sublingual apomorphine
WO2011130608A1 (en) * 2010-04-15 2011-10-20 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
AU2011343429B2 (en) 2010-12-16 2016-10-20 Sunovion Pharmaceuticals Inc. Sublingual films
EP3581567A1 (en) 2011-04-10 2019-12-18 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
WO2016172095A1 (en) 2015-04-21 2016-10-27 Cynapsus Therapeutics, Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
WO1993023035A2 (en) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE69514794T2 (de) * 1994-04-22 2000-07-27 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
PE20000240A1 (es) 2000-03-31
TNSN99008A1 (fr) 2005-11-10
BG64667B1 (bg) 2005-11-30
GT199900013A (es) 2001-07-20
NO319821B1 (no) 2005-09-19
IL137569A (en) 2006-08-01
SK11362000A3 (sk) 2001-02-12
MA26600A1 (fr) 2004-12-20
EP1056419A1 (en) 2000-12-06
BG104715A (bg) 2001-02-28
AU2564499A (en) 1999-08-16
TR200002220T2 (tr) 2000-12-21
NZ506597A (en) 2003-07-25
IL137569A0 (en) 2001-07-24
HUP0101268A2 (hu) 2001-09-28
CN1313742A (zh) 2001-09-19
JO2085B1 (en) 2000-05-21
CN1250221C (zh) 2006-04-12
DZ2714A1 (fr) 2003-09-01
GC0000096A (en) 2005-06-29
NO20003845D0 (no) 2000-07-27
HN1999000015A (es) 1999-08-23
PA8467801A1 (es) 2000-09-29
AU752928B2 (en) 2002-10-03
US6193992B1 (en) 2001-02-27
ZA99686B (en) 1999-07-28
AR017976A1 (es) 2001-10-24
HK1040901B (zh) 2006-11-24
PL342062A1 (en) 2001-05-21
HUP0101268A3 (en) 2002-12-28
KR20010040477A (ko) 2001-05-15
BR9908038A (pt) 2002-01-02
MXPA00007447A (es) 2006-01-25
EP1056419A4 (en) 2007-05-02
CA2322289A1 (en) 1999-08-05
PL194350B1 (pl) 2007-05-31
CO4970819A1 (es) 2000-11-07
HK1040901A1 (en) 2002-06-28
US5945117A (en) 1999-08-31
JP2002501875A (ja) 2002-01-22
TW550069B (en) 2003-09-01
NO20003845L (no) 2000-09-28
WO1999038467A1 (en) 1999-08-05
CR5959A (es) 1999-07-28

Similar Documents

Publication Publication Date Title
UY25374A1 (es) Composiciones de apomorfina útiles en el tratamiento de disfunción sexual femenina
US6465512B2 (en) Leukemic cell growth inhibiting method
AR100291A2 (es) Composición catártica
BR9302738A (pt) Composicao oral substancialmente nao irritante,com sabor aceitavel
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
EP0151989A3 (en) Means for the treatment of cardiac diseases
CO5590913A2 (es) Terapia de combinacion antivirica
MD1688F2 (en) Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
KR970025615A (ko) 암 전이 억제제
ES2108240T3 (es) Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor.
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
CO4960654A1 (es) Metodo para el tratamiento de enfermedades fisiologicas relacionadas con el uso o con las secuelas provocadas por el uso de la ***a u otros estimulantes psicomotores
PE33396A1 (es) Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar
AR041069A1 (es) Composicion de tolterodina liquida oral
ES2115571T3 (es) Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
KR910009267A (ko) 우울증의 치료방법
ES2067206T3 (es) Composiciones farmaceuticas conteniendo 3-amino-epsilon-caprolactamas para estimular el proceso de aprendizaje y la memoria.
CO5021217A1 (es) Composiciones estables de mitoxantrona, procedimietno para prepararlas; utilizacion de dichas composiciones y medica- mentos que incluyen dichas soluciones para el tratamiento de enfermedades cancerosas
IS6555A (is) Meðferð með aðskildum skömmtum sem hafa æðaskaðandi virkni
ES2111013T3 (es) Una composicion profilactica/terapeutica que contiene ws7622a para evitar o tratar la coagulacion intravascular diseminada, la enfermedad infecciosa cronica del tracto respiratorio o la bronquitis cronica.
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120117